Literature DB >> 22354544

Interferon therapy and prevention of hepatocellular carcinoma in hepatitis C.

Amit G Singal, Jorge A Marrero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22354544     DOI： 10.1007/s10620-012-2069-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  20 in total

1.  Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy.

Authors:  Yasuji Komorizono; Katsumi Sako; Naruhiro Yamasaki; Takuya Hiwaki; Kazuhiro Sakurai; Toshihiko Shibatou; Masahiko Maeda; Kazunori Kohara; Shuhou Shigenobu; Sususmu Hasegawa; Takushi Arima; Makoto Oketani; Kazuaki Ishibashi; Terukatsu Arima
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

2.  Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

Authors:  Takahiro Uenishi; Shoji Kubo; Kazuhiro Hirohashi; Hiromu Tanaka; Taichi Shuto; Takatsugu Yamamoto; Akihiro Tamori; Seikan Hai; Hiroaki Kinoshita; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2002-12       Impact factor: 4.288

3.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

4.  Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Takahiro Uenishi; Shuhei Nishiguchi; Akihiro Tamori; Takatsugu Yamamoto; Taichi Shuto; Kazuhiro Hirohashi; Shigekazu Takemura; Hiromu Tanaka; Shoji Kubo
Journal:  Hepatol Res       Date:  2006-08-24       Impact factor: 4.288

5.  Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial.

Authors:  C L Lai; J Y Lau; P C Wu; H Ngan; H T Chung; S J Mitchell; T J Corbett; A W Chow; H J Lin
Journal:  Hepatology       Date:  1993-03       Impact factor: 17.425

6.  Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

Authors:  Jordi Bruix; Thierry Poynard; Massimo Colombo; Eugene Schiff; Kelly Burak; Elizabeth J L Heathcote; Thomas Berg; Jorge-Luis Poo; Carlos Brandao Mello; Rainer Guenther; Claus Niederau; Ruben Terg; Pierre Bedossa; Navdeep Boparai; Louis H Griffel; Margaret Burroughs; Clifford A Brass; Janice K Albrecht
Journal:  Gastroenterology       Date:  2011-03-17       Impact factor: 22.682

7.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

8.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

Authors:  Hiroshi Imamura; Yutaka Matsuyama; Eiji Tanaka; Takao Ohkubo; Kiyoshi Hasegawa; Shinichi Miyagawa; Yasuhiko Sugawara; Masami Minagawa; Tadatoshi Takayama; Seiji Kawasaki; Masatoshi Makuuchi
Journal:  J Hepatol       Date:  2003-02       Impact factor: 25.083

9.  Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

Authors:  S Nishiguchi; T Kuroki; S Nakatani; H Morimoto; T Takeda; S Nakajima; S Shiomi; S Seki; K Kobayashi; S Otani
Journal:  Lancet       Date:  1995-10-21       Impact factor: 79.321

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425
View more
  2 in total

1.  Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.

Authors:  N Saraiya; A C Yopp; N E Rich; M Odewole; N D Parikh; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2018-05-30       Impact factor: 8.171

Review 2.  Exosomes as potent regulators of HCC malignancy and potential bio-tools in clinical application.

Authors:  Zhen Qu; Chunping Jiang; Junhua Wu; Yitao Ding
Journal:  Int J Clin Exp Med       Date:  2015-10-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.